
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity is viewed favorably because its Life Sciences segment is reaccelerating, with 9% organic sales growth well above the 5.5% estimate, improving instrument demand, and stronger reagent trends supported by recovering biopharma and academic spending. Diagnostics also looks more durable and profitable, as pro forma gross margin reached 62.4% and Diagnostics operating margin improved nearly 900 bps quarter over quarter, aided by the Euroimmun restructuring and resilient immunodiagnostics and reproductive health demand. The outlook is further strengthened by Signals’ sticky software base, broad AI-related tailwinds, and new launches like Xynthetica, BioDesign, and LabGistics, which could support above-LRP growth and higher-margin revenue streams.
Bears say
Revvity is facing a fundamental growth gap because its two largest businesses, Immunodiagnostics and Life Sciences Solutions, represent about 70% of revenue yet still need clear acceleration to justify the long-range plan. Diagnostics organic growth of 5% slightly missed the 5.5% forecast, ex-China immunodiagnostics ran at +MSD/HSD% versus a 9–11% expectation, and Life Sciences Solutions only recently returned to +LSD% growth after contracting in 2024 and 2025. Reproductive health is also set up less favorably as GEL annualizes in Q4 '26, global birth rates are declining, and competition is intensifying from BD/Waters, Abcam/Danaher, Roche, Diasorin, and AI-native software rivals.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Revvity Inc (RVTY) Forecast
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares